MSD & # 39; Elbevo & # 39; Prevents Zyr Ebola Virus Infection
Congo use prevention plans to send vaccines in third quarter of 2020
The world's first Ebola vaccine has been licensed in Europe.
The European Medicines Agency has granted the conditional release of the Ebola vaccine, “ Ervebo & # 39; & # 39; '', developed by MSD, as a vaccine to prevent Ebola virus infection caused by Zyr Ebola virus in older people. 18 years old.
Prior to this approval, Elbevo was designated for rapid review in Europe, and the European Medicines Agency's Advisory Committee on Drugs (CHMP) recommended conditional approval for Elbebo last month.
Elbevo has been selected for the FDA's rapid review in the US and is undergoing a license review and will be approved in March next year.
Following a massive Ebola outbreak in West Africa in 2014, 11,000 people died and the second deadly Ebola incident in the Democratic Republic of Congo killed 2,200 people. In response to these emergencies, Elbevo has been used preventively in Congo.
With approval, MSD plans to manufacture the vaccine for a licensed supply from a German factory and will be shipped in the third quarter of 2020. In addition, the company evaluated the approval as a historic achievement, a milestone that represents the power of science, innovation. and public-private partnerships. It will work closely with Gavi, the Vaccine Alliance.
Elbevo, meanwhile, was originally developed by the National Institutes of Biology of the Canadian Department of Public Health and licensed by NewLink Generics. Since then, MSD licensed during the 2014 Ebola outbreak and has continued to develop partner vaccines.
Copyright © Palm News Prohibited unauthorized reproduction and redistribution